Semax + Selank Blend

The Semax + Selank Blend is a dual-peptide research formulation pairing two short regulatory peptides developed in Russia for the study of cognition, neuroprotection, anxiety, and stress adaptation. Each 20mg vial contains 10mg of Semax and 10mg of Selank as a co-lyophilized powder, allowing investigators to evaluate the combined activity of two complementary neuroactive sequences in a single preparation.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) modified to enhance metabolic stability. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the immunomodulatory peptide tuftsin, also engineered for prolonged in vivo activity. Both peptides have been studied extensively in preclinical and clinical research models for nootropic, anxiolytic, and neuroprotective effects.

The blend is intended for laboratory research applications investigating overlapping and synergistic effects of these two peptides on memory, attention, anxiety-like behavior, and neurochemical signaling.

The blend combines two mechanistically distinct but complementary peptide systems active within the central nervous system.

Semax — Melanocortin and Neurotrophic Pathways

Semax modulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), supporting synaptic plasticity and neuronal survival. It interacts with melanocortin receptors and influences dopaminergic and serotonergic signaling, contributing to its reported effects on attention, learning, and memory consolidation in research models.

Selank — GABAergic and Immunomodulatory Pathways

Selank exerts anxiolytic-like effects through modulation of GABA receptor expression and serotonergic transmission without producing sedation or dependence in animal studies. It also influences expression of cytokines and enkephalin-degrading enzymes, linking peripheral immune signaling with central neurochemistry.

Combined Activity

Co-administration in research models targets parallel cognitive and affective pathways: Semax's nootropic and neurotrophic actions complement Selank's anxiolytic and immunomodulatory effects, providing a single tool for investigating combined neuroprotective, cognitive, and stress-response endpoints.

Both component peptides have a substantial body of preclinical and clinical research published primarily in Russian-language journals, with a growing number of English-language reviews and translational studies.

Cognitive and Nootropic Research

Semax has been studied for effects on attention, working memory, and cognitive performance in healthy and impaired research models. Investigations include effects on cortical BDNF expression, post-ischemic recovery, and protection against oxidative neuronal injury.

Anxiolytic and Stress Research

Selank has been examined in models of generalized anxiety, chronic stress, and adaptation. Studies report reductions in anxiety-like behaviors, modulation of GABAergic tone, and changes in expression of stress-related genes without the motor or cognitive side effects associated with classical benzodiazepines.

Neuroprotection

Both peptides have been investigated in cerebral ischemia and stroke recovery models, with reports of reduced neuronal loss, preserved neurological function, and modulation of neurotrophic factor signaling.

Translational Studies

Combination research is more limited but exploratory studies have evaluated parallel administration to characterize additive effects on memory tasks, anxiety paradigms, and neurochemical markers.

Both Semax and Selank have demonstrated favorable safety profiles in preclinical and clinical research, with low reported toxicity and minimal adverse events at investigated doses.

Reported Effects

Mild and infrequent effects reported in research include transient nasal irritation (intranasal administration), mild headache, and short-lived changes in alertness. Neither peptide has shown significant sedative, dependence-forming, or withdrawal-related properties in published studies.

Combination Considerations

Long-term combination data is limited. Researchers should follow appropriate handling, dosing, and documentation practices when working with combined peptide preparations.

Research Use Only

This product is intended solely for laboratory research purposes and is not approved for human or veterinary therapeutic use.